Hypocretin Antagonists as a Novel Approach to Medication Development
下丘脑分泌素拮抗剂作为药物开发的新方法
基本信息
- 批准号:8106887
- 负责人:
- 金额:$ 41.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAgonistAmphetaminesAppetitive BehaviorArousalAttenuatedBananaBehaviorBrainCandyClinicalCocaineCocaine DependenceComplexCuesDataDevelopmentDoseDropsDrug abuseEatingEating DisordersFoodFood deprivation (experimental)GlucoseGoalsHydrocortisoneHypothalamic structureIncentivesInfusion proceduresInsulinLateralLearningMacaca mulattaMeasuresMediatingMemoryModelingMonkeysNeuronsNeuropeptidesPapioPharmaceutical PreparationsPlayProceduresPsychological reinforcementRelapseRodentRoleSelf AdministrationSelf-AdministeredStressSystemTechniquesbasedeprivationdisorder later incidence preventiondrug relapsefood consumptionfood flavorhypocretinimprovednonhuman primatenovelnovel strategiesnovel therapeutic interventionorexin Aorexin Bpaired stimulipreferencereinforced behaviorreinforcerresponsestressor
项目摘要
DESCRIPTION (provided by applicant): The neuropeptides hypocretin-1 and -2 (de Lecea et al., 1998) also known as orexin-A and -B (Sakurai et al., 1998) derive from the lateral hypothalamus and project throughout the brain. Hypocretin plays a role in modulating arousal, foraging for food in rodents, the response to stress, and learning and memory. Hypocretins also play a role in drug-reinforced behavior by modulating 1) the salience of stimuli paired with drug, as assessed using condition-place preference models, 2) the magnitude of response to drug following repeated dosing, i.e., sensitization, and 3) the ability of environmental cues and stress to elicit reinstatement in relapse models. These data suggest that hypocretin-mediated arousal has motivating effects and increases the salience of cues associated with reinforcement. Given the societal problems of eating disorders and cocaine- dependence, a carefully controlled assessment of the influence of hypocretin agonists and antagonists on cocaine- and food-seeking and self-administration in non-human primates is highly significant. Aim 1a: Determine the effects of a hypocretin-1 antagonist, and agonist and agonist/antagonist combinations on the appetitive and consummatory aspects of responding for banana-flavored food pellets by 6 rhesus monkeys. Acute i.v. insulin administration causes a rapid drop in glucose levels an increase in cFos activation in hypothalamic hypocretin neurons and cortisol. We will use insulin infusions to naturally increase hypocretin activity. Aim 1b: Determine the effects of insulin-induced hypocretin activation on hypocretin levels, the appetitive and consummatory aspects of responding for banana-flavored food pellets, and if the effects can be attenuated by a hypocretin-1 antagonist. Aim 2: Determine the effects of a hypocretin-1 antagonist and agonist and agonist/antagonist combinations on the appetitive and consummatory aspects of cocaine self-administration and responding for candy by rhesus monkeys, and determine if the effects of a stressor can be attenuated by a hypocretin-1 antagonist. Our second goal is to examine the effects of hypocretin manipulations on reinstatement of responding reinforced by cocaine and candy. We will use a choice procedure in which monkeys choose to take candy or self-administer cocaine. Aim 3: Determine if a hypocretin-1 antagonist can block reinstatement of responding previously reinforced with cocaine or candy in rhesus monkeys induced by 1) a hypocretin-1 agonist; 2) insulin-induced hypocretin activation; 3) cues paired with the commodity; and 4) the commodity itself. A choice procedure will allow us to demonstrate the selectivity of reinstatement blockade by the antagonist. Impact: Because the hypocretin system plays a complex modulatory role in a wide range of behaviors, we believe that this 2-step approach of first analyzing non-specific, incentive effects of hypocretin manipulations and then the specific effects of a hypocretin antagonist on drug reinstatement will provide the basis for using hypocretins as a novel therapeutic approach for drug abuse, as well as eating disorders.
PUBLIC HEALTH RELEVANCE: Hypocretins, by virtue of their involvement in a wide range of behaviors, e.g., drug taking, arousal, provide a novel arena for medication development. Improved medications for drug abuse will have immediate clinical impact.
描述(由申请人提供):神经肽-1和-2(De Lecea等人,1998),也称为食欲素-A和-B(Sakurai等人,1998),来自下丘脑外侧,投射到整个大脑。下丘脑泌素在调节唤醒、啮齿动物觅食、对压力的反应以及学习和记忆方面发挥作用。亚克汀类在药物强化行为中也发挥作用,通过调节1)与药物配对的刺激的显著程度,如使用条件-地点偏好模型评估的那样,2)重复给药后对药物的反应的大小,即敏化,以及3)环境线索和应激在复发模型中诱导恢复的能力。这些数据表明,下丘脑泌素介导的唤醒具有激励作用,并增加了与强化相关的线索的显着性。考虑到饮食失调和可卡因依赖的社会问题,仔细控制地评估下丘脑泌素激动剂和拮抗剂对非人类灵长类动物的可卡因和寻找食物以及自我管理的影响是非常重要的。目的1a:用6只恒河猴测定下丘脑泌素-1拮抗剂、激动剂和激动剂/拮抗剂组合对香蕉味食物颗粒反应的食欲和消耗方面的影响。急性静脉注射。注射胰岛素会导致血糖水平迅速下降,下丘脑下丘脑、下丘脑和皮质醇中CFOS活性增加。我们将使用胰岛素输注来自然增加下丘脑泌素的活性。目的1b:确定胰岛素诱导的下丘脑肌素激活对下丘脑肌素水平的影响,香蕉味食物颗粒反应的食欲和消耗性方面,以及下丘脑肌素-1拮抗剂是否能减弱这种影响。目的:研究下丘脑泌素-1拮抗剂、激动剂和激动剂/拮抗剂组合对恒河猴对可卡因自身给药和对糖的反应的食欲和消耗性方面的影响,并确定应激源的影响是否可以被下丘脑泌素-1拮抗剂减弱。我们的第二个目标是研究下丘脑泌素对可卡因和糖果强化的反应恢复的影响。我们将使用一个选择程序,在这个程序中,猴子选择吃糖果或自我注射可卡因。目的3:确定一种降克素-1拮抗剂是否能阻止1)降克素-1激动剂;2)胰岛素诱导的降克素激活;3)与商品配对的线索;以及4)商品本身所引起的恒河猴先前用可卡因或糖果加强的反应的恢复。选择程序将使我们能够证明对手恢复封锁的选择性。影响:由于下丘脑肌素系统在广泛的行为中起着复杂的调节作用,我们相信,这种首先分析下丘脑肌素操纵的非特异性刺激效应,然后分析下丘脑肌素拮抗剂对药物恢复的具体影响的两步方法将为将下丘脑肌素用作药物滥用和饮食障碍的新治疗方法提供基础。
与公共健康相关:下丘脑分泌物,由于它们参与了广泛的行为,例如,吸毒,唤醒,为药物开发提供了一个新的舞台。药物滥用药物的改进将立即产生临床影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard W Foltin其他文献
Richard W Foltin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard W Foltin', 18)}}的其他基金
Automated Speech Analysis: A Marker of Drug Intoxication & Treatment Outcome
自动语音分析:药物中毒的标志
- 批准号:
9232130 - 财政年份:2016
- 资助金额:
$ 41.19万 - 项目类别:
Impulsivity In Cocaine Abusers: Relationship to Drug Taking and Treatment Outcome
可卡因滥用者的冲动:与吸毒和治疗结果的关系
- 批准号:
8694439 - 财政年份:2014
- 资助金额:
$ 41.19万 - 项目类别:
Impulsivity In Cocaine Abusers: Relationship to Drug Taking and Treatment Outcome
可卡因滥用者的冲动:与吸毒和治疗结果的关系
- 批准号:
9040137 - 财政年份:2014
- 资助金额:
$ 41.19万 - 项目类别:
Impulsivity In Cocaine Abusers: Relationship to Drug Taking and Treatment Outcome
可卡因滥用者的冲动:与吸毒和治疗结果的关系
- 批准号:
9252429 - 财政年份:2014
- 资助金额:
$ 41.19万 - 项目类别:
Hypocretin Antagonists as a Novel Approach to Medication Development
下丘脑分泌素拮抗剂作为药物开发的新方法
- 批准号:
8233458 - 财政年份:2011
- 资助金额:
$ 41.19万 - 项目类别:
Clinical and Preclinical Models in Drug Abuse: Training and Development
药物滥用的临床和临床前模型:培训和开发
- 批准号:
8685228 - 财政年份:2011
- 资助金额:
$ 41.19万 - 项目类别:
Clinical and Preclinical Models in Drug Abuse: Training and Development
药物滥用的临床和临床前模型:培训和开发
- 批准号:
8488420 - 财政年份:2011
- 资助金额:
$ 41.19万 - 项目类别:
Hypocretin Antagonists as a Novel Approach to Medication Development
下丘脑分泌素拮抗剂作为药物开发的新方法
- 批准号:
8445339 - 财政年份:2011
- 资助金额:
$ 41.19万 - 项目类别:
Clinical and Preclinical Models in Drug Abuse: Training and Development
药物滥用的临床和临床前模型:培训和开发
- 批准号:
8286888 - 财政年份:2011
- 资助金额:
$ 41.19万 - 项目类别:
Clinical and Preclinical Models in Drug Abuse: Training and Development
药物滥用的临床和临床前模型:培训和开发
- 批准号:
8164971 - 财政年份:2011
- 资助金额:
$ 41.19万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 41.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 41.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 41.19万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 41.19万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 41.19万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 41.19万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 41.19万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 41.19万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 41.19万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 41.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)